It was previously shown that brain tissue from STZ-treated rodents presents reduced insulin-signaling pathway activity and increased GSK3β activity, concomitant with impaired cognitive behavior and the appearance of AD hallmarks [26]. This evidence concerns the gene GSK3B and Alzheimer disease.